U.S. pharmaceutical company Major Rugby has announced a nationwide recall of 12 commonly used prescription thyroid medications, specifically Levothyroxine Sodium Tablets, due to concerns over reduced drug potency.
The recall was initiated following a report from the U.S. Food and Drug Administration (FDA) and an official notice issued by the company to retailers. The affected batches were identified as "sub-potent," meaning the actual amount of active ingredient released from the drug is lower than the labeled standard. The recalled products were sold under the Major and Cardinal brand names, with the relevant batches having been distributed across the United States starting in January 2025.
Levothyroxine Sodium Tablets are clinically used to treat hypothyroidism, goiter, and certain types of thyroid cancer. Regarding the potential risks from this drug defect, Major Rugby stated that taking the affected batches is "unlikely to cause adverse health effects." The company has urged consumers to return the affected medications to their original place of purchase and advised patients who already possess the drugs to consult their primary care physician for evaluation.
The specific products covered by this recall include 7 different strengths, ranging from 25 micrograms to 150 micrograms, in blister packs of 10 and 100 tablets. The expiration dates for the affected batches fall between July 2026 and January 2027.
Comments